The NANOS Annual Meeting Neuro-Ophthalmology Collection: Presentations from the annual meeting of the North American Neuro-Ophthalmology Society (NANOS), a professional organization of more than 600 members who are fully trained ophthalmologists or neurologists. Contains records from the first meeting in 1975 to the present.
NOVEL: https://novel.utah.edu/
TO
| Title | Creator | Relation Is Part Of | ||
|---|---|---|---|---|
| 126 |
 |
Natalizumab Reduces Loss of Visual Function in Patients with Relapsing Multiple Sclerosis | L. Balcer; S. Galetta; P. O'Connor; E. Hardova; M. Hutchinson; L. Kappos; D. Miller; J. Phillips; C. Polman. W. Stuart; P. Calabresi. C. Confavreux; E. Radue; R. Rudick; F. Lublin. G. Giovannoni. A. Wajgt. B. Weinstock-Guttman. D. Wynn. F. Lynn; M. Panzara; A. Sandrock | NANOS 2006: Scientific Platform Presentations (Session II) |
| 127 |
 |
Neuro-Ophthalmic Consequences of Medications for Multiple Sclerosis: The Good, The Bad, The Ugly and The Unknown (abstract) | Heather E. Moss, MD, PhD | NANOS 2017: Neuro-Ophthalmologic Side Effects of More Recently Used Medications in Treating Cancer, Rheumatologic Disorders, and Multiple Sclerosis |
| 128 |
 |
Neuro-Ophthalmic Consequences of Medications for Multiple Sclerosis: The Good, The Bad, The Ugly and The Unknown (video) | Heather E. Moss, MD, PhD | NANOS Annual Meeting 2017: Neuro-Ophthalmologic Side Effects of More Recently Used Medications in Treating Cancer, Rheumatologic Disorders, and Multiple Sclerosis |
| 129 |
 |
Neuroimaging in Multiple Sclerosis and Optic Neuritis | Neil R. Miller | NANOS 1996: Multiple Sclerosis Symposium |
| 130 |
 |
Neuroimaging of Multiple Sclerosis: New Frontiers | Matilde Inglese | NANOS 2008: Diagnostic Neuroimaging |
| 131 |
 |
Neuromyelitis Optica - Devic's Disease | James J. Corbett, MD | MRI vs. All Other Modalities in the Diagnosis of Multiple Sclerosis Symposium |
| 132 |
 |
Neuromyelitis Optica, Is It a Distinct Entity from MS and What Are the Treatment Implications? | Jeffrey L. Bennett, MD, PhD; Steven Galetta, MD | NANOS 2010: Controversies in Neuroophthalmology |
| 133 |
 |
Neuroprotection in Optic Neuritis: A Clinical Trial | Laura J. Balcer | NANOS 2007: Novel Approaches to Treatment of Neuro-Ophthalmic Diseases: Part I: Neuroprotection and Other Methods for Salvaging Visual Function |
| 134 |
 |
Neuroprotective Effects of ST266 in Experimental Optic Neuritis (.pdf) | Kenneth S. Shindler; Reas S Khan; Kimberly Dine; Larry Brown | NANOS Annual Meeting 2016: Scientific Platform Session II |
| 135 |
 |
New Imaging Techniques in Multiple Sclerosis | Robert I. Grossman | NANOS 2001: Optic Neuritis and Multiple Sclerosis Symposium |
| 136 |
 |
New Onset Asymmetric Bilateral Visual Field Defect After Sequential Retrobulbar Neuritis in a Patient with Multiple Sclerosis | H. E. Killer, MD; B. J. Wicki; R. H. Laeng | NANOS 2000: Poster Presentations |
| 137 |
 |
New Therapies for Multiple Sclerosis, Beyond the ABCs | Ari J. Green | NANOS Annual Meeting Journal Club, 2015 |
| 138 |
 |
New Therapies for Multiple Sclerosis, Beyond the ABCs | Ari J. Green | NANOS Annual Meeting Journal Club, 2015 |
| 139 |
 |
New Therapies for Multiple Sclerosis, Beyond the ABCs (video) | Ari J. Green | NANOS Annual Meeting Journal Club, 2015 |
| 140 |
 |
New Treatments for Multiple Sclerosis | Barry G. W. Amason | NANOS 1996: Multiple Sclerosis Symposium |
| 141 |
 |
New Treatments for Multiple Sclerosis | Sashank Prasad | NANOS Annual Meeting 2019: New Information I Should Know |
| 142 |
 |
New Treatments for Multiple Sclerosis | Sashank Prasad | NANOS 2019: New Information I Should Know |
| 143 |
 |
Normal Appearing Brain Tissue MTR Predicts Clinical Recovery from Acute Optic Neuritis in MS | Gregory Van Stavern; Omar Khan; Jai Perumal | NANOS 2009: Scientific Platform Presentations (Session I) |
| 144 |
 |
OCT-3 Quality Control in Two Multi-Center Multiple Sclerosis (MS) Therapeutic Trials | John Keltner; Kimberly Cello; Laura Balcer; Peter Calabresi; Clyde Markowitz; John Werner | NANOS 2010: Poster Presentations |
| 145 |
 |
One Eye or Two: the Advantage and Significance of Binocular Low-Contrast Acuity Testing in Multiple Sclerosis | Stacy L .Pineles; Eileen Birch; Lauren Talman; David Sackel; Amy Conger; Dina Jacobs; Clyde Markowitz; Gui-Shuang Ying; Yang Dai; Maureen Maguire; Elliot Frohman; Peter Calabresi; Steven Galetta; Laura Balcer | NANOS 2010: Scientific Platform Presentations |
| 146 |
 |
One Eye or Two: the Advantage and Significance of Binocular Low-Contrast Acuity Testing in Multiple Sclerosis | Stacy L .Pineles; Eileen Birch; Lauren Talman; David Sackel; Amy Conger; Dina Jacobs; Clyde Markowitz; Gui-Shuang Ying; Yang Dai; Maureen Maguire; Elliot Frohman; Peter Calabresi; Steven Galetta; Laura Balcer | NANOS 2010: Scientific Platform Presentations |
| 147 |
 |
One Year Multiple Sclerosis Conversion Rates for Patients with Multifocal Visual Evoked Potential (MVEP) Latency Delay | C. Fraser; A. Klistorner; S; Graham; R. Garrick; F. Billson; J. Grigg | NANOS 2006: Scientific Platform Presentations (Session I) |
| 148 |
 |
ONTT (Optic Neuritis Treatment Trial) Update | Craig H. Smith, MD | NANOS 2001: Optic Neuritis and Multiple Sclerosis Symposium |
| 149 |
 |
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis (MS) | Marco Zarbin; Anthony T. Reder; William Collins; Gordon Francis; Xiaoli Zhang; Ludwig Kappos; Jeffrey A. Cohen | NANOS 2012: Poster Presentations |
| 150 |
 |
Opsoclonus and Ocular Flutter in Multiple Sclerosis | Christian Wertenbaker, MD; Marc Ellman, MD | NANOS 2003: Poster Presentations |